These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34003484)

  • 1. Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.
    Zelei T; Mendola ND; Elezbawy B; Németh B; Campbell JD
    Pharmacoecon Open; 2021 Dec; 5(4):605-612. PubMed ID: 34003484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.
    Su P; Zhi K; Xu H; Xiao J; Liu J; Wang Z; Liu Q; Yu Y; Dang H
    Front Pharmacol; 2024; 15():1245825. PubMed ID: 38720775
    [No Abstract]   [Full Text] [Related]  

  • 3. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).
    Villanueva V; Carreño M; Gil-Nagel A; Serrano-Castro PJ; Serratosa JM; Toledo M; Álvarez-Barón E; Gil A; Subías-Labazuy S
    Epilepsy Behav; 2021 Sep; 122():108222. PubMed ID: 34371462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
    Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
    Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.
    Jakab I; Németh B; Elezbawy B; Karadayı MA; Tozan H; Aydın S; Shen J; Kaló Z
    Front Pharmacol; 2020; 11():1203. PubMed ID: 32922287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
    Angelis A; Kanavos P
    Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
    Blonda A; Denier Y; Huys I; Simoens S
    Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
    [No Abstract]   [Full Text] [Related]  

  • 12. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rapid Literature Review of Multi-Criteria Decision Support Methods in the Context of One Health for All-Hazards Threat Prioritization.
    Zhao J; Smith T; Lavigne M; Aenishaenslin C; Cox R; Fazil A; Johnson A; Sanchez J; Hermant B
    Front Public Health; 2022; 10():861594. PubMed ID: 35493347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.
    Badia X; Aguarón A; Fernández A; Gimón A; Nafria B; Gaspar B; Guarga L; Gálvez M; Fuentes M; Paco N; Saldaña R
    Int J Technol Assess Health Care; 2019 Jan; 35(1):56-63. PubMed ID: 30730288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Schey C; Krabbe PF; Postma MJ; Connolly MP
    Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of relevant information around non-core domains to support Multi-Criteria Decision Analysis (MCDA) for decision making.
    Bayón-Yusta JC; Gutiérrez-Iglesias A; Galnares-Cordero L; Gutiérrez-Ibarluzea I
    GMS Health Innov Technol; 2024; 18():Doc02. PubMed ID: 38655192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches.
    Vásquez P; Hall L; Merlo G
    Value Health Reg Issues; 2024 Jul; 44():101026. PubMed ID: 39059264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.